FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317105895> ?p ?o ?g. }

• W2317105895 endingPage "173" @default.
• W2317105895 startingPage "161" @default.
• W2317105895 abstract "Abstract The crucial role of tumor-associated fibroblasts (TAF) in cancer progression is now clear in non–small cell lung cancer (NSCLC). However, therapies against TAFs are limited due to a lack of understanding in the subtype-specific mechanisms underlying their accumulation. Here, the mechanical (i.e., matrix rigidity) and soluble mitogenic cues that drive the accumulation of TAFs from major NSCLC subtypes: adenocarcinoma (ADC) and squamous cell carcinoma (SCC) were dissected. Fibroblasts were cultured on substrata engineered to exhibit normal- or tumor-like stiffnesses at different serum concentrations, and critical regulatory processes were elucidated. In control fibroblasts from nonmalignant tissue, matrix stiffening alone increased fibroblast accumulation, and this mechanical effect was dominant or comparable with that of soluble growth factors up to 0.5% serum. The stimulatory cues of matrix rigidity were driven by β1 integrin mechano-sensing through FAK (pY397), and were associated with a posttranscriptionally driven rise in β1 integrin expression. The latter mechano-regulatory circuit was also observed in TAFs but in a subtype-specific fashion, because SCC–TAFs exhibited higher FAK (pY397), β1 expression, and ERK1/2 (pT202/Y204) than ADC–TAFs. Moreover, matrix stiffening induced a larger TAF accumulation in SCC–TAFs (&gt;50%) compared with ADC–TAFs (10%–20%). In contrast, SCC–TAFs were largely serum desensitized, whereas ADC–TAFs responded to high serum concentration only. These findings provide the first evidence of subtype-specific regulation of NSCLC–TAF accumulation. Furthermore, these data support that therapies aiming to restore normal lung elasticity and/or β1 integrin-dependent mechano regulation may be effective against SCC–TAFs, whereas inhibiting stromal growth factor signaling may be effective against ADC–TAFs. Implications: This study reveals distinct mechanisms underlying the abnormal accumulation of tumor-supporting fibroblasts in two major subtypes of lung cancer, which will assist the development of personalized therapies against these cells. Mol Cancer Res; 13(1); 161–73. ©2014 AACR." @default.
• W2317105895 created "2016-06-24" @default.
• W2317105895 creator A5004635907 @default.
• W2317105895 creator A5011222937 @default.
• W2317105895 creator A5013127109 @default.
• W2317105895 creator A5015738860 @default.
• W2317105895 creator A5029087392 @default.
• W2317105895 creator A5033472633 @default.
• W2317105895 creator A5037713370 @default.
• W2317105895 creator A5040466055 @default.
• W2317105895 creator A5056168484 @default.
• W2317105895 creator A5064772186 @default.
• W2317105895 creator A5070222807 @default.
• W2317105895 creator A5073347748 @default.
• W2317105895 creator A5087391532 @default.
• W2317105895 date "2015-01-01" @default.
• W2317105895 modified "2023-10-13" @default.
• W2317105895 title "Matrix Stiffening and β1 Integrin Drive Subtype-Specific Fibroblast Accumulation in Lung Cancer" @default.
• W2317105895 cites W1559823239 @default.
• W2317105895 cites W1594207045 @default.
• W2317105895 cites W1978252135 @default.
• W2317105895 cites W1981641897 @default.
• W2317105895 cites W1989095124 @default.
• W2317105895 cites W1994843494 @default.
• W2317105895 cites W2007040134 @default.
• W2317105895 cites W2008387441 @default.
• W2317105895 cites W2012124753 @default.
• W2317105895 cites W2012473086 @default.
• W2317105895 cites W2016613783 @default.
• W2317105895 cites W2016996307 @default.
• W2317105895 cites W2027691370 @default.
• W2317105895 cites W2058186388 @default.
• W2317105895 cites W2062176937 @default.
• W2317105895 cites W2069532196 @default.
• W2317105895 cites W2072278671 @default.
• W2317105895 cites W2075078693 @default.
• W2317105895 cites W2078502914 @default.
• W2317105895 cites W2079347556 @default.
• W2317105895 cites W2081854922 @default.
• W2317105895 cites W2086336177 @default.
• W2317105895 cites W2091590272 @default.
• W2317105895 cites W2097059887 @default.
• W2317105895 cites W2098852983 @default.
• W2317105895 cites W2099052265 @default.
• W2317105895 cites W2100303404 @default.
• W2317105895 cites W2104479723 @default.
• W2317105895 cites W2105072296 @default.
• W2317105895 cites W2111547416 @default.
• W2317105895 cites W2114717603 @default.
• W2317105895 cites W2125586870 @default.
• W2317105895 cites W2126486146 @default.
• W2317105895 cites W2134208433 @default.
• W2317105895 cites W2147451740 @default.
• W2317105895 cites W2154279182 @default.
• W2317105895 cites W2159731793 @default.
• W2317105895 cites W2162884347 @default.
• W2317105895 cites W2165022280 @default.
• W2317105895 cites W2170030318 @default.
• W2317105895 cites W2314203153 @default.
• W2317105895 cites W2325727928 @default.
• W2317105895 cites W4211133103 @default.
• W2317105895 cites W79277247 @default.
• W2317105895 doi "https://doi.org/10.1158/1541-7786.mcr-14-0155" @default.
• W2317105895 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25280968" @default.
• W2317105895 hasPublicationYear "2015" @default.
• W2317105895 type Work @default.
• W2317105895 sameAs 2317105895 @default.
• W2317105895 citedByCount "43" @default.
• W2317105895 countsByYear W23171058952015 @default.
• W2317105895 countsByYear W23171058952016 @default.
• W2317105895 countsByYear W23171058952017 @default.
• W2317105895 countsByYear W23171058952018 @default.
• W2317105895 countsByYear W23171058952019 @default.
• W2317105895 countsByYear W23171058952020 @default.
• W2317105895 countsByYear W23171058952021 @default.
• W2317105895 countsByYear W23171058952022 @default.
• W2317105895 countsByYear W23171058952023 @default.
• W2317105895 crossrefType "journal-article" @default.
• W2317105895 hasAuthorship W2317105895A5004635907 @default.
• W2317105895 hasAuthorship W2317105895A5011222937 @default.
• W2317105895 hasAuthorship W2317105895A5013127109 @default.
• W2317105895 hasAuthorship W2317105895A5015738860 @default.
• W2317105895 hasAuthorship W2317105895A5029087392 @default.
• W2317105895 hasAuthorship W2317105895A5033472633 @default.
• W2317105895 hasAuthorship W2317105895A5037713370 @default.
• W2317105895 hasAuthorship W2317105895A5040466055 @default.
• W2317105895 hasAuthorship W2317105895A5056168484 @default.
• W2317105895 hasAuthorship W2317105895A5064772186 @default.
• W2317105895 hasAuthorship W2317105895A5070222807 @default.
• W2317105895 hasAuthorship W2317105895A5073347748 @default.
• W2317105895 hasAuthorship W2317105895A5087391532 @default.
• W2317105895 hasBestOaLocation W23171058951 @default.
• W2317105895 hasConcept C142724271 @default.
• W2317105895 hasConcept C1491633281 @default.
• W2317105895 hasConcept C189165786 @default.
• W2317105895 hasConcept C195687474 @default.
• W2317105895 hasConcept C2776256026 @default.
• W2317105895 hasConcept C2780381497 @default.

• next